Clinical Study of Sorafenib Combined With Gefitinib for Treating Pancreatic Neuroendocrine Tumors That Progressed After Previous Treatments

What this Trial Is About

Pancreatic neuroendocrine neoplasms (pNENs) are tumors whose incidence is rising, with survival rates varying widely depending on the stage of disease. Existing treatments like somatostatin analogues, chemotherapy, and targeted drugs such as sunitinib and everolimus have limited effectiveness, especially for patients with disease progression or drug resistance. Research indicates that the epidermal growth factor receptor (EGFR) pathway may be a promising target for therapy due to its role in tumor progression and poorer survival outcomes in some patients. This study evaluates the combination of sorafenib, an oral tyrosine kinase inhibitor targeting VEGFR, FGFR1, and CSF1R, with gefitinib, an EGFR inhibitor, to improve treatment outcomes in patients with pancreatic neuroendocrine tumors who have progressed after prior therapies. Participants will take sorafenib 250 mg and gefitinib 250 mg orally once daily. The study aims to assess whether this dual-targeted approach can enhance anti-tumor effects by inhibiting angiogenesis and modulating immune responses. Participants will undergo baseline examinations followed by assessments every 8 weeks for up to 2 years to measure tumor response. Survival evaluations will also be conducted every 12 weeks during this period. Researchers will monitor objective response rates and progression-free survival to determine treatment activity and safety. The study involves regular clinical and laboratory assessments to ensure participant safety and treatment adherence throughout the trial.

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET